Bilihome, founded in 2019 in The Netherlands, is revolutionizing neonatal care with its innovative product: a wearable jaundice therapy device designed for natural newborn care. The brainchild of a concerned parent, this company emerged from a personal quest to improve postnatal outcomes by enabling phototherapy treatment at home.
Operating at the intersection of Care Economy, Fashion, Health Care, Health and Wellness, and Medical Devices, Bilihome is redefining neonatal health protocols. Their intuitive solution offers convenience and efficiency, minimizing extended hospital stays and associated stress for new families.
Supported by NLC – The European Healthtech Venture Builder, Bilihome recently secured a €140.00K seed investment from Health Venture as of 01 June 2024. This funding underscores the growing confidence in the company's potential to significantly impact newborn care globally.